New Limited Partners Joined to NEXTBLUEⅡ Limited Partnership

ASKA Pharmaceutical Co., Ltd., and Others Join NEXTBLUE for Investment in Japanese and European Startups and Support for New Market Expansion

NEXTBLUEⅡ Limited Partnership (Location: Chuo-ku, Tokyo; Representative Partners: Kanako Inoue, Yuichi Kori, Vincent Tan) is pleased to announce the participation of ASKA Pharmaceutical Co., Ltd. (Headquarters: Minato-ku, Tokyo; CEO: Sota Yamaguchi), along with multiple individual investors, in the closing of the NEXTBLUEⅡ Investment Limited Partnership (hereinafter referred to as “NEXTBLUEⅡ Fund”), which specializes in the area of women’s wellbeing. This is in addition to the initial participants at the fund’s establishment: JERA Co., Inc., SUNNY SIDE UP Inc., and individual investors in December 2023.

The NEXTBLUEⅡ Fund, established in September 2023, aims to invest in startups and female entrepreneurs offering services in the area of women’s wellbeing. The fund is committed to contributing to a society where everyone can find their place and thrive, positioning the improvement of women’s “wellbeing” as a key step towards this goal.

Asuka Pharmaceuticals, which signed the participation agreement this time, operates under the management philosophy of “Contributing to people’s health and the future of medicine through advanced drug discovery.” The company, leveraging its expertise in hormones, focuses on the development of pharmaceuticals for medical use. As part of its mid-term management plan 2025, Asuka Pharmaceuticals aims to become a “total healthcare company based on specialty pharma.”

By welcoming Asuka Pharmaceuticals, a leading company in the field of obstetrics and gynecology dedicated to solving women’s health issues, as a partner, the fund aims to create social impact towards improving the wellbeing of women across Japan. This endeavor is expected to transform the “economic loss” faced by the Japanese society into “productivity enhancement,” focusing on realizing women’s wellbeing.

About ASKA Pharmaceutical Co., Ltd.

Since its establishment in 1920, under the management philosophy of “Contributing to people’s health and the future of medicine through advanced drug discovery,” Asuka Pharmaceuticals has been focusing on the three key areas of internal medicine, obstetrics and gynecology, and urology. The company actively develops new pharmaceuticals, concentrating its management resources in these areas to address medical needs.

Official Website:

Partners: Kanako Inoue, Vincent Tan, Yuichi Kori
Location: 3-1-3 Nihonbashi, Chuo-ku, Tokyo, 2nd Floor, xBridge-Global
Established: May 11, 2023
Business Activities: Entrepreneur support, management of investment Limited Partnerships, attracting European companies to Japan, and facilitating Japanese companies’ expansion into Europe

After graduating from Hitotsubashi University, Yuichi worked at companies such as RenRen and F-code, before then founding Otsumu in 2010. From 2015, he supported various accelerator programs (such as the program with Asahi Newspaper), and from 2017 started and began operating his own VC fund called Reality Accelerator.

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.